At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 59 enrolled
Drug / intervention
Gefapixant +1 moredrug
Likely dose
Gefapixant 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Dose Escalation Study to Assess the Efficacy and Tolerance of AF-219 in Subjects With Refractory Chronic Cough
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·interventional·Posted Jan 28, 2015·Updated Oct 22, 2020
In Brief
A Phase 2 clinical trial evaluating Gefapixant and Placebo (for gefapixant) for Refractory Chronic Cough. Completed, enrolled 59 participants.
Detailed Summary
A randomized, double-blind, placebo-controlled, crossover, dose escalation study to assess the efficacy and tolerability of gefapixant (AF-219; MK-7264) in participants with refractory chronic cough.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Chronic Cough
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartMar 2015
Primary CompletionFeb 2016
Study CompletionFeb 2016
TodayJul 2026
First PostedJan 28, 2015
Enrollment StartMar 9, 2015
Primary CompletionFeb 1, 2016
Study CompletionFeb 9, 2016
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 11.4 years ago
Interventions
Gefapixantdrug
Gefapixant 7.5 and 50mg tablets administered orally
Placebo (for gefapixant)drug
Placebo to gefapixant 7.5 and 50mg tablets administered orally